A number of other research analysts have also recently issued reports on the company. Zacks Investment Research cut BioXcel Therapeutics from a hold rating to a sell rating in a research note on Monday, August 12th. HC Wainwright set a $25.00 price objective on BioXcel Therapeutics and gave the company a buy rating in a research note on Wednesday, June 5th.
Shares of NASDAQ:BTAI opened at $9.12 on Tuesday. The stock has a fifty day simple moving average of $9.99 and a two-hundred day simple moving average of $10.01. The stock has a market capitalization of $143.47 million, a price-to-earnings ratio of -6.91 and a beta of 3.02. BioXcel Therapeutics has a 12-month low of $2.41 and a 12-month high of $12.00. The company has a current ratio of 3.93, a quick ratio of 3.93 and a debt-to-equity ratio of 0.04.
BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.02). As a group, equities research analysts predict that BioXcel Therapeutics will post -2.22 EPS for the current year.
In other BioXcel Therapeutics news, Director Peter Mueller purchased 8,446 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was purchased at an average price of $8.74 per share, for a total transaction of $73,818.04. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Vimal Mehta purchased 2,983 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was acquired at an average price of $8.64 per share, with a total value of $25,773.12. The disclosure for this purchase can be found here. Insiders have acquired 18,976 shares of company stock valued at $165,104 in the last quarter. 64.80% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of BTAI. BlackRock Inc. raised its stake in shares of BioXcel Therapeutics by 1,988.0% in the second quarter. BlackRock Inc. now owns 299,145 shares of the company’s stock worth $3,278,000 after purchasing an additional 284,818 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of BioXcel Therapeutics by 45.4% in the second quarter. Vanguard Group Inc. now owns 259,301 shares of the company’s stock worth $2,842,000 after purchasing an additional 80,959 shares during the last quarter. Northern Trust Corp raised its stake in shares of BioXcel Therapeutics by 247.7% in the second quarter. Northern Trust Corp now owns 43,822 shares of the company’s stock worth $481,000 after purchasing an additional 31,218 shares during the last quarter. Creative Planning purchased a new position in shares of BioXcel Therapeutics in the first quarter worth $302,000. Finally, Renaissance Technologies LLC raised its stake in shares of BioXcel Therapeutics by 59.8% in the second quarter. Renaissance Technologies LLC now owns 71,600 shares of the company’s stock worth $785,000 after purchasing an additional 26,800 shares during the last quarter. Hedge funds and other institutional investors own 17.61% of the company’s stock.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Featured Story: What is a Reverse Stock Split?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.